Raymond James Financial Services Advisors Inc. bought a new stake in shares of Embecta Corp. (NASDAQ:EMBC – Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,933 shares of the company's stock, valued at approximately $488,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. bought a new position in shares of Embecta during the third quarter valued at approximately $27,000. Copeland Capital Management LLC purchased a new stake in shares of Embecta during the third quarter valued at approximately $28,000. Bartlett & Co. LLC purchased a new stake in shares of Embecta during the third quarter valued at approximately $41,000. Hall Laurie J Trustee purchased a new stake in shares of Embecta during the third quarter valued at approximately $42,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of Embecta during the third quarter valued at approximately $42,000. Institutional investors own 93.45% of the company's stock.

Embecta Trading Up 6.4 %

NASDAQ:EMBC opened at $25.21 on Thursday. The company's 50 day moving average price is $28.75 and its 200-day moving average price is $29.51. Embecta Corp. has a 52 week low of $22.30 and a 52 week high of $49.00.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 11th. Investors of record on Friday, December 30th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend was Thursday, December 29th.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley cut shares of Embecta from an "equal weight" rating to an "underweight" rating and set a $28.00 price target on the stock. in a report on Friday, January 6th.

About Embecta

(Get Rating)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.

See Also

• Get a free copy of the StockNews.com research report on Embecta (EMBC)
• AMD Is Still One Of The Best Semiconductor Stocks Out There
• Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
• Is The Bottom In For Cyber-Security Stocks?
• Union Pacific, Norfolk Southern Pull into Buying Zone
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Get Rating).

Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.